PulmCCM - Feb 12, 2015
"The U.S. FDA continued its flurry of new antibiotic approvals to close out 2014, giving the nod to ceftolozane with tazobactam. The drug will be marketed as Zerbaxa by the pharmaceutical company Cubist.
Ceftolozane is a novel cephalosporin, combined with the existing β-lactamase inhibitor tazobactam in the new product. Zerbaxa has broad activity against gram-negative bacteria, includingEnterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa, as well as against gram positives includingBacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius...
Ceftolozane/tazobactam will initially have indications for complicated intra-abdominal infections and complicated urinary tract infections. Trials testing Zerbaxa for ventilator-associated pneumonia are in process.
"Other antibiotics approved in 2014 include three new agents with activity againstmethicillin-resistant Staphylococcus aureus (MRSA), indicated for acute skin and soft tissue infections in adults:
- Tedizolid (Sivextro), available oral or IV, and active against Gram-positive bacteria including Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus inosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.
- Dalbavancin (Dalvance), indicated for a similar antimicrobial spectrum as tedizolid, minus E. faecalis. Dalvance is available through the IV route only, but has the advantage of requiring only two 30-minute infusions one week apart.
- Oritavancin (Orbactiv), with a similar antimicrobial spectrum as Sivextro, but given as a single IV dose to replace a 7-day course of vancomycin."
http://pulmccm.org/main/2015/infectious-disease-sepsis-review/fda-approves-ceftolozanetazobactam-zerbaxa-5th-new/